2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide

C38H42Br2N16O — CID 143656310

IUPAC2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide
SMILESCN(C)C(=O)Cn1cc(-c2cnn3c(N)c(Br)c(C4CCCN(c5ccc(Cn6cc(-c7cnn8c(N)c(Br)c(C9CCCNC9)nc78)cn6)nc5)C4)nc23)cn1
InChIInChI=1S/C38H42Br2N16O/c1-51(2)30(57)21-54-19-25(13-46-54)29-16-48-56-36(42)32(40)34(50-38(29)56)23-6-4-10-52(17-23)27-8-7-26(44-14-27)20-53-18-24(12-45-53)28-15-47-55-35(41)31(39)33(49-37(28)55)22-5-3-9-43-11-22/h7-8,12-16,18-19,22-23,43H,3-6,9-11,17,20-21,41-42H2,1-2H3
InChIKeyRZXQJEOUYQRKKZ-UHFFFAOYSA-N
MW898.67 g/mol
LogP4.57
Rot. Bonds9

About 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide

2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide (PubChem CID 143656310) has the molecular formula C38H42Br2N16O and a molecular weight of 898.67 g/mol. Its IUPAC name is 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide.

Molecular Properties

Compound Name2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide
PubChem CID143656310
Molecular FormulaC38H42Br2N16O
Molecular Weight898.67 g/mol
Exact Mass896.21
IUPAC Name2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide
SMILESCN(C)C(=O)Cn1cc(-c2cnn3c(N)c(Br)c(C4CCCN(c5ccc(Cn6cc(-c7cnn8c(N)c(Br)c(C9CCCNC9)nc78)cn6)nc5)C4)nc23)cn1
InChIInChI=1S/C38H42Br2N16O/c1-51(2)30(57)21-54-19-25(13-46-54)29-16-48-56-36(42)32(40)34(50-38(29)56)23-6-4-10-52(17-23)27-8-7-26(44-14-27)20-53-18-24(12-45-53)28-15-47-55-35(41)31(39)33(49-37(28)55)22-5-3-9-43-11-22/h7-8,12-16,18-19,22-23,43H,3-6,9-11,17,20-21,41-42H2,1-2H3
InChIKeyRZXQJEOUYQRKKZ-UHFFFAOYSA-N
XLogP4.57
TPSA196.53 Ų
H-Bond Donors3
H-Bond Acceptors16
Rotatable Bonds9
Heavy Atoms57
Complexity

Lipinski Rule of Five

2 violations

RuleValue
MW ≤ 500898.67
LogP ≤ 54.57
H-Bond Donors ≤ 53
H-Bond Acceptors ≤ 1016

Analyze 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide?
The IUPAC name of 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide (CID 143656310) is 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide.
What is the SMILES notation for 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide?
The canonical SMILES for 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide is CN(C)C(=O)Cn1cc(-c2cnn3c(N)c(Br)c(C4CCCN(c5ccc(Cn6cc(-c7cnn8c(N)c(Br)c(C9CCCNC9)nc78)cn6)nc5)C4)nc23)cn1.
What is the InChIKey of 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide?
The InChIKey is RZXQJEOUYQRKKZ-UHFFFAOYSA-N. The full InChI is InChI=1S/C38H42Br2N16O/c1-51(2)30(57)21-54-19-25(13-46-54)29-16-48-56-36(42)32(40)34(50-38(29)56)23-6-4-10-52(17-23)27-8-7-26(44-14-27)20-53-18-24(12-45-53)28-15-47-55-35(41)31(39)33(49-37(28)55)22-5-3-9-43-11-22/h7-8,12-16,18-19,22-23,43H,3-6,9-11,17,20-21,41-42H2,1-2H3.
What are the key properties of 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide?
2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide has a molecular weight of 898.67 g/mol, XLogP of 4.57, 9 rotatable bonds, 3 hydrogen bond donors, and 16 hydrogen bond acceptors.
Where does this data come from?
All data for 2-[4-[7-amino-5-[1-[6-[[4-(7-amino-6-bromo-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-3-yl)pyrazol-1-yl]methyl]-3-pyridinyl]piperidin-3-yl]-6-bromopyrazolo[1,5-a]pyrimidin-3-yl]pyrazol-1-yl]-N,N-dimethylacetamide is sourced from PubChem (CID 143656310), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).